Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 5/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | UNG | P13051 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | POLR1A | O95602 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279575 | 0.82 | HPGD (0.59) | PARP1ROCK2ROCK1SCN9AHDAC6 | |
| SCHEMBL31188482 | 0.82 | ADRB1 (0.60) | PARP1ROCK2ROCK1SCN9AIKBKB | |
| SCHEMBL5088410 | 0.82 | ADRB1 (0.60) | PARP1ROCK2ROCK1SCN9AIKBKB | |
| SCHEMBL8274391 | 0.82 | ADRB1 (0.60) | PARP1ROCK2ROCK1SCN9AIKBKB | |
| SCHEMBL10380819 | 0.81 | ROCK2 (0.58) | PARP1ROCK2ROCK1SCN9AMEN1 | |
| SCHEMBL20344071 | 0.79 | CYP1A2 (0.58) | PARP1ROCK2ROCK1SCN9AMEN1 | |
| SCHEMBL17790228 | 0.79 | ROCK2 (0.61) | PARP1ROCK2ROCK1SCN9AIKBKB | |
| SCHEMBL8288130 | 0.79 | ALDH1A1 (0.53) | PARP1ROCK2ROCK1SCN9AMEN1 | |
| SCHEMBL15652763 | 0.78 | SMYD3 (0.55) | PARP1MEN1KMT2AHDAC6UNG | |
| SCHEMBL6221703 | 0.78 | ADRB1 (0.59) | PARP1SCN9AIKBKBADRB1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150080426-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | AUSPEX PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PARP1 2361/4885ROCK2 258/4885ROCK1 225/4885 |
| US-20150080426-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | SLC18A2, ACAT2, SLC6A2 | PARP1 3126/4885ROCK2 2219/4885ROCK1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.